|
Palatin Tech To Cut Work Force In Half, Do Reverse Stock Split
Wall Street Journal Palatin has been developing bremelanotide for male and female sexual dysfunction and PL-3994 for acute severe asthma. The company plans to submit plans for … Palatin Announces Strategic Realignment of Operations Palatin Reducing Workforce By 50%; To Effect 1-for-10 Reverse Stock Split … |
View full post on asthma – Google News